Amyris has agreed to acquire Oobli, combining the sweet protein developer’s fermentation technology with its strain engineering and manufacturing capabilities.
The transaction is expected to close in the coming weeks. Existing Oobli customer commitments and brand partnerships will continue without interruption.
Oobli’s commercial sweet protein portfolio will be the first area supported by the combined platform. The company has spent a decade developing fermentation processes for proteins originally found in fruits and berries near the equator.
Its products include Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, scientifically known as brazzein, monellin and thaumatin.
The ingredients are intended to help food and beverage companies reduce sugar while retaining sweetness. Oobli says its portfolio has generally recognized as safe status for ingredient use and is affirmed for use as natural flavor by the Flavor and Extract Manufacturers Association.
Potential applications include beverages, dairy, sports nutrition, chocolate, baked goods and confectionery.
The acquisition follows Amyris’s manufacturing expansion at its fermentation facility in Barra Bonita, Brazil, earlier in 2026.
Amyris sees the transaction as both a commercial expansion and an addition to its technology capabilities, extending its work in protein- and peptide-based ingredients.
Beyond sweeteners, management identified possible applications across personal care, flavors and fragrances, agriculture and other markets.
Founded in 2003, Amyris develops specialty molecules through fermentation for customers in food, beauty, advanced materials and other industries.
The combination connects Oobli’s protein development expertise with a larger manufacturing platform. Its near-term focus is scaling existing sweet protein products, while the broader rationale is to expand the range of fermentation-based solutions Amyris can develop and commercialize.
KEY QUOTES:
“In Oobli, we see a commercial and technology platform that is a great complement to our own. Oobli is poised to transform how sweetness makes it to market, and we are thrilled to bring our commercial scale and resources to further accelerate the sweet revolution. Further, by bringing Oobli’s protein expertise together with our strain engineering, manufacturing scale, and commercial capabilities, we see the potential to broaden our capabilities in food and beverage, personal care, flavor and fragrances, agriculture, and beyond, expanding the ways we can help customers innovate.”
“At Amyris, we’ve seen that biomanufactured solutions win when they align with consumer demand and market needs. Oobli’s sweet protein platform does exactly that – giving brands a new way to deliver on sweet taste, sugar reduction, and clean label all at the same time. We could not be more excited to welcome the Oobli team into the Amyris family and collectively realize the synergies between our two innovative platforms.”
Kathy Fortmann, CEO Of Amyris
“At Oobli, we have always believed there was a better way to deliver the sweet taste consumers love, without the trade-offs to health and our environment. It is with immense pride that we look back on the breakthroughs we have achieved. Joining forces with Amyris gives us the scale and resources to realize our ambition of making sweet proteins the global standard in sweetness solutions. Sweet proteins are an idea whose time is now.”
Ali Wing, CEO Of Oobli

